These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 9269651)

  • 21. The use of intravenous and intraperitoneal desferrioxamine in aluminium osteomalacia.
    O'Brien AA; McParland C; Keogh JA
    Nephrol Dial Transplant; 1987; 2(2):117-9. PubMed ID: 3112649
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of ultrafiltration and chromatography to assess aluminum speciation in serum after deferoxamine administration.
    Canteros-Picotto A; Fernández-Martín JL; Cannata-Andía JB
    Am J Kidney Dis; 2000 Nov; 36(5):969-75. PubMed ID: 11054353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adequacy of dialysis: trace elements in dialysis fluids.
    D'Haese PC; De Broe ME
    Nephrol Dial Transplant; 1996; 11 Suppl 2():92-7. PubMed ID: 8804004
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Haemofiltration or haemodialysis in aluminium elimination?
    Sulkova S; Laurincova Z; Válek A
    Nephrol Dial Transplant; 1991; 6 Suppl 3():3-5. PubMed ID: 1775263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased silicon levels in dialysis patients due to high silicon content in the drinking water, inadequate water treatment procedures, and concentrate contamination: a multicentre study.
    D'Haese PC; Shaheen FA; Huraib SO; Djukanovic L; Polenakovic MH; Spasovski G; Shikole A; Schurgers ML; Daneels RF; Lamberts LV
    Nephrol Dial Transplant; 1995 Oct; 10(10):1838-44. PubMed ID: 8592591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Desferrioxamine treatment of osteomalacia caused by aluminum poisoning].
    Charhon SA; Chavassieux P; Chapuy MC; Accominotti M; Traeger J; Meunier PJ
    Presse Med; 1986 Jan; 15(2):55-9. PubMed ID: 2935857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent developments in aluminum toxicology.
    Monteagudo FS; Cassidy MJ; Folb PI
    Med Toxicol Adverse Drug Exp; 1989; 4(1):1-16. PubMed ID: 2651849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low percentage of aluminoxamine and ferrioxamine in uremic serum after desferrioxamine administration.
    Menéndez-Fraga P; Fernández-Martín JL; Blanco-González E; Cannata-Andía JB
    Clin Chem; 1998 Jun; 44(6 Pt 1):1262-8. PubMed ID: 9625051
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anomalous rise of serum osteocalcin following desferrioxamine treatment in aluminium intoxication.
    Davie MW; Worsfold M; Sharp CA; Perks J; Day JP
    Nephron; 1993; 65(2):245-8. PubMed ID: 8247187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correction of haemodialysis-associated anaemia by deferoxamine. Effects on serum aluminum and iron overload.
    von Bonsdorff M; Sipilä R; Pitkänen E
    Scand J Urol Nephrol Suppl; 1990; 131():49-54. PubMed ID: 2075470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reversible microcytic hypochromic anaemia in dialysis patients due to aluminium intoxication.
    Short AI; Winney RJ; Robson JS
    Proc Eur Dial Transplant Assoc; 1980; 17():226-33. PubMed ID: 7243773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resistance to recombinant human erythropoietin due to aluminium overload and its reversal by low dose desferrioxamine therapy.
    Yaqoob M; Ahmad R; McClelland P; Shivakumar KA; Sallomi DF; Fahal IH; Roberts NB; Helliwell T
    Postgrad Med J; 1993 Feb; 69(808):124-8. PubMed ID: 8506193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Desferrioxamine treatment for aluminium and iron overload in uraemic patients by haemodialysis or haemofiltration.
    Baldamus CA; Schmidt H; Scheuermann EH; Werner E; Kaltwasser JP; Schoeppe W
    Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():382-6. PubMed ID: 3991527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Desferrioxamine-induced changes of aluminium kinetics during haemodialysis.
    Graf H; Stummvoll HK; Meisinger V
    Proc Eur Dial Transplant Assoc; 1981; 18():674-80. PubMed ID: 7329995
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Renal osteodystrophy (3); its treatment in dialysis patients].
    Ghitu S; Oprisiu R; Benamar L; Said S; Tataru Albu A; Arsenescu I; el Esper N; Morinière P; Fournier A
    Nephrologie; 2000; 21(8):413-24. PubMed ID: 11213385
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Affinity of the aluminium binding protein.
    Rahman H; Skillen AW; Ward MK; Channon SM; Kerr DN
    Int J Artif Organs; 1986 Mar; 9(2):93-6. PubMed ID: 3699915
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of fracturing renal osteodystrophy by desferrioxamine.
    Ackrill P; Day JP; Garstang FM; Hodge KC; Metcalfe PJ; Benzo Z; Hill K; Ralston AJ; Ball J; Denton J
    Proc Eur Dial Transplant Assoc; 1983; 19():203-7. PubMed ID: 6878234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exacerbation of aluminium encephalopathy after treatment with desferrioxamine.
    Lillevang ST; Pedersen FB
    Nephrol Dial Transplant; 1989; 4(7):676. PubMed ID: 2510071
    [No Abstract]   [Full Text] [Related]  

  • 39. [Effect of deferoxamine on erythropoiesis in patients hemodialyzed for chronic renal insufficiency treated with erythropoietin].
    Kalinowski M; Popławski A; Kaliszewski Z; Juzwiuk J
    Pol Merkur Lekarski; 1996 Oct; 1(4):232-4. PubMed ID: 9156931
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Dialysis encephalopathy and aluminum poisoning? Correlated clinical, pathologic-anatomic and spectrometric findings].
    Weiller C; Spiegel P; Van de Vijver F
    Nervenarzt; 1986 Aug; 57(8):461-4. PubMed ID: 3092120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.